Advancing Preventive Vascular Inflammation in the South with SmartVascular Dx™ TestIRVINE, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce the expansion of the SmartVascular Dx™ test (formally known as the PULS™ Cardiac Test) into southern states.
SmartVascular Dx™ Test: Enhancing Vascular Care in the MidwestIRVINE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), is a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce its expansion in the Midwest with the introduction of the SmartVascular Dx™ test (formally known as the PULS™ Cardiac Test), a groundbreaking tool designed to improve vascular health outcomes.
Expanding Access in California: SmartVascular Dx™ Test Now Available Through Major Health PlansIRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests that address unmet clinical needs, is excited to announce that the SmartVascular Dx™ test (formally known as the PULS™ Cardiac Test) is now accessible to patients throughout California. This expansion comes through strategic partnerships with major health plans, including L.A. Care Health Plan and Health Net.
SmartVascular™ Test: Revolutionizing Vascular Risk Assessment NationwideIRVINE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- MorningStar Laboratories, LLC (“MSL” or “the Company”), a leading developer of precision diagnostic tests that address unmet clinical needs, proudly announces its SmartVascular Dx™ (SVDx) test (formally known as the PULS Cardiac test), designed to transform the early detection and management of vascular health, empowering healthcare providers to implement proactive strategies that significantly enhance patient outcomes.
